Skip to content

Proto Labs PRLB Granted (in shares)

Granted (in shares) at other companies

West Pharmaceutical Services logo
West Pharmaceutical ServicesWST

Other financials

Income statement

See full
Revenue$139.3M+10.4%
Gross profit$63.6M+14.2%
Operating income$9.8M+117%
Net income$8.1M+125%
EPS (diluted)$0.33+120%

Balance sheet

See full
Cash & equivalents$124.0M+49.9%
Total debt$2.6M-16.6%
Total equity$683.1M+4.0%
Total assets$778.6M+5.6%

Cash flow

See full
Operating cash flow$17.5M-4.6%
CapEx$3.5M+181%
Free cash flow$14.0M-18.2%

Valuation

See full
Market cap$1.9B+59.7%

Profitability

See full
Gross margin44.9%+0.5pp
Operating margin5.6%+1.7pp
Net margin4.7%+1.6pp
FCF margin10.4%-3.1pp

Returns & leverage

See full
Return on equity3.8%+1.6pp
Debt / equity0.0×
Current ratio3.5×+0.4×

Where this comes from

Reported directly by Proto Labs in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice.

The official record: Proto Labs’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Proto Labs's granted (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Proto Labs's granted (in shares)?
Proto Labs (PRLB) reported granted (in shares) of $62.63 in Q1 2026.
How has Proto Labs's granted (in shares) changed year-over-year?
Proto Labs's granted (in shares) increased by 58.1% year-over-year, from $39.61 to $62.63.
What does granted (in shares) mean?
The weighted average exercise price of stock options granted to employees and directors during the reporting period. This metric reflects the company's cost of equity-based incentives and the strike price set for new option awards.